IMMIX BIOPHARMA, INC.

(IMMX)
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
2.120 USD   +30.06%
05/20Top Midday Gainers
MT
05/20Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & Johnson Unit's Trabectedin in Mice Study
MT
05/20ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Immix Biopharma Shares More Than Double on FDA Designation

01/03/2022 | 12:18pm EDT

By Colin Kellaher

Shares of Immix Biopharma Inc. more than doubled on Monday after the biopharmaceutical company's lead product candidate received rare-pediatric-disease designation from the U.S. Food and Drug Administration.

The Los Angeles company said the designation covers IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of pediatric cancer.

Immix is currently studying IMX-110 in a Phase 1b/2a clinical trial.

Companies that FDA approval of a drug granted the rare-pediatric-disease designation receive a priority-review voucher that they can use to obtain priority review for another drug or sell to other companies.

Mirum Pharmaceuticals Inc., Albireo Pharma Inc. and Liminal BioSciences Inc. all sold vouchers last year, taking in more than $100 million apiece.

Such an infusion would be a boon to Immix, which raised about $21 million in its initial public offering last month and reported having cash of less than $38,000 as of Sept. 30, prior to the IPO.

Immix shares, which rose as high as $6.31 in their trading debut on Dec. 17, were recently changing hands at $7.40, up 108% after hitting $8.68 early in the session.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

01-03-22 1218ET

Stocks mentioned in the article
ChangeLast1st jan.
ALBIREO PHARMA, INC. 0.68% 22.32 Delayed Quote.-4.16%
IMMIX BIOPHARMA, INC. 30.06% 2.12 Delayed Quote.-40.45%
MIRUM PHARMACEUTICALS, INC. 5.66% 25.58 Delayed Quote.60.38%
All news about IMMIX BIOPHARMA, INC.
05/20Top Midday Gainers
MT
05/20Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & J..
MT
05/20ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration ..
AQ
05/20Immix Biopharma, Inc. Announces Positive Interim Study Data Showing That After One Cycl..
CI
05/13IMMIX BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/13Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/09Immix Biopharma Announces Share Repurchase Program
AQ
05/09Immix Biopharma, Inc. authorizes a Buyback Plan.
CI
05/09Immix Biopharma, Inc. announces an Equity Buyback for $1 million worth of its shares.
CI
04/05ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX A..
AQ
More news
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 29,4 M 29,4 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees 2
Free-Float 37,4%
Chart IMMIX BIOPHARMA, INC.
Duration : Period :
Immix Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMIX BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Managers and Directors
Ilya Rachman Chairman & Chief Executive Officer
Gabriel A. Morris Chief Financial Officer & Director
Graham Ross Chief Medical Officer & Head-Clinical Development
Helen C. Adams Independent Director
Jane Melissa Buchan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMIX BIOPHARMA, INC.-40.45%29
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612